Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Delphinidin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 3/20 | 0.83 |
| ▸ | EGFR known ✓ | P00533 | 2/20 | 0.80 |
| ▸ | KDR known ✓ | P35968 | 2/20 | 0.80 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.56 |
| ▸ | CD38 | P28907 | 11/20 | 0.86 |
| ▸ | F2 | P00734 | 2/20 | 0.86 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.86 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.86 |
| ▸ | GLO1 | Q04760 | 5/20 | 0.83 |
| ▸ | SNCA | P37840 | 4/20 | 0.83 |
| ▸ | EP300 | Q09472 | 2/20 | 0.80 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.80 |
| ▸ | OR51E2 | Q9H255 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyanidin SCHEMBL1644900 | 0.94 | CD38 (0.97) | CD38F2NR1H2NR1H3GLO1 | |
| Cyanidin SCHEMBL608392 | 0.94 | CD38 (0.97) | CD38F2NR1H2NR1H3GLO1 | |
| Cyanidin SCHEMBL7931530 | 0.93 | GLO1 (0.97) | CD38F2NR1H2NR1H3GLO1 | |
| Cyanidin SCHEMBL29414396 | 0.93 | CD38 (1.00) | CD38F2NR1H2NR1H3GLO1 | |
| Cyanidin SCHEMBL20799 | 0.93 | CD38 (1.00) | CD38F2NR1H2NR1H3GLO1 | |
| Cyanidin SCHEMBL29742342 | 0.91 | CD38 (0.97) | CD38F2NR1H2NR1H3GLO1 | |
| Cyanidin SCHEMBL156277 | 0.91 | GLO1 (1.00) | CD38F2NR1H2NR1H3GLO1 | |
| Cyanidin SCHEMBL30423220 | 0.91 | CD38 (0.97) | CD38F2NR1H2NR1H3GLO1 | |
| Cyanidin SCHEMBL29547214 | 0.91 | GLO1 (1.00) | CD38F2NR1H2NR1H3GLO1 | |
| Cyanidin SCHEMBL1945495 | 0.90 | CD38 (0.88) | CD38F2NR1H2NR1H3GLO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240191273-A1 | ANTHOCYANIN BIOPRODUCTION IN A CELL-FREE MANUFACTURING SYSTEM | Debut Biotechnology, Inc. | 2024-06-13 | — | — | US | disclosed |
| US-9078872-B2 | Antioxidant composition | SYMRISE AG (DE) | 2015-07-14 | — | — | US | disclosed |
| US-20140309294-A1 | ANTIOXIDANT COMPOSITION | SYMRISE AG (DE) | 2014-10-16 | — | — | US | disclosed |
| WO-2014062538-A1 | POLYSACCHARIDE-CONTAINING HYDROGELS, COMPOSITIONS, ARTICLES, AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-04-24 | — | — | WO | disclosed |
| EP-0537429-B1 | Modified huminates, process for obtaining the same and their uses | RUETGERSWERKE AG (DE) | 1996-06-12 | — | — | EP | disclosed |
| EP-0537429-A1 | Modified huminates, process for obtaining the same and their uses | RÜTGERSWERKE AKTIENGESELLSCHAFT (DE) | 1993-04-21 | — | — | EP | disclosed |
| US-PP6378-P | Geranium plant \"Calypso\ | RESEARCH CORPORATION (US) | 1988-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309294-A1 | ANTIOXIDANT COMPOSITION | CAT, GPX1, GPX4 | DPP4 685/4885EGFR 4884/4885KDR 4764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.